Sponsor: 
Sanofi-Aventis Australia
Administration route: 
Intramuscular injection
Vaccine group: 
Combination vaccines

Registered for use in infants and children aged ≥6 weeks.

DTPa-hepB-IPV-Hib — diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b combination vaccine

Each 0.5 mL monodose pre-filled syringe contains:

  • ≥20 IU diphtheria toxoid
  • ≥40 IU tetanus toxoid
  • 25 µg pertussis toxoid
  • 25 µg filamentous haemagglutinin
  • 10 µg recombinant hepatitis B surface antigen (HBsAg)
  • 40 D-antigen units inactivated poliovirus type 1 (Mahoney)
  • 8 D-antigen units inactivated poliovirus type 2 (MEF-1)
  • 32 D-antigen units inactivated poliovirus type 3 (Saukett)
  • 12 µg purified Hib capsular polysaccharide conjugated to 22–36 µg tetanus toxoid

Adsorbed onto 0.6 mg aluminium as aluminium hydroxide.

May contain traces of:

  • glutaraldehyde
  • formaldehyde
  • neomycin
  • streptomycin
  • polymyxin B

For full details, refer to the product information and consumer medicine information sheets for Hexaxim vaccine available on the TGA website.

Page history

Last updated: 
4 June 2018
Last reviewed: 
4 June 2018

Definitions

DTPa
diphtheria-tetanus-acellular pertussis vaccine
IPV
inactivated poliomyelitis vaccine
IU
international units
HBsAg
hepatitis B surface antigen